Good News for People Newly Diagnosed with MOGAD: Most People in a Study Recovered, and Few Had Another Attack

Good News for People Newly Diagnosed with MOGAD: Most People in a Study Recovered, and Few Had Another Attack

As shared on EurekAlert, a study of children and adults newly diagnosed with MOGAD found that most recovered fully. Fewer than 12% had another attack during the follow-up period.

MOGAD stands for myelin oligodendrocyte glycoprotein antibody-associated disease. It is a rare condition that causes inflammation in the central nervous system—the brain, spinal cord, and optic nerves. It can cause serious symptoms.

Researchers at Kaiser Permanente Southern California followed 69 people from their first recognized MOGAD attack. Over a median follow-up of about 32 months:

  • 57 of the 69 people (more than 80%) recovered fully.
  • 8 people (just under 12%) had another attack.
  • 3 people had moderate-to-severe lasting effects.

The study found a lower rate of repeat attacks than some earlier research, which estimated that 40% to 50% of people with MOGAD relapse. Earlier studies often came from specialist centers, which may have cared for more people with severe or recurring disease. This study followed patients in a broader health care population, starting with their first recognized attack.

The low rate of repeat attacks was seen even though relatively few people in the study received preventive immune treatments or long-term corticosteroids.

“Being diagnosed with MOGAD can be frightening because the first attack can cause serious neurological symptoms,” said lead author Annette M. Langer-Gould, MD, PhD, a neuroimmunologist and researcher at Kaiser Permanente. She said the results suggest that many people can expect a full recovery, with a relatively low chance of another attack.

More research is needed to learn who is most likely to have another attack and how long treatment should continue for people who do.